By Sneha S K and Christy Santhosh (Reuters) -AbbVie plans to "commit less capital" towards experimental medicines for ...

Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

AbbVie will commit "less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...

Last week, AbbVie said that it would record a charge of about $3.5 billion related to the drug. The company is looking to compete with Bristol Myers Squibb's (BMY.N), opens new tab Cobenfy ...